USA imposes 100% import duty on certain patented pharmaceuticals
→Pharmaceutical importers' customs teams face 100% tariff on patented-drug consignments
Change
USA imposed a 100% ad valorem import duty on certain patented pharmaceuticals and associated pharmaceutical ingredients via an April 2 executive order.
Why it matters
Imports of the specified patented pharmaceuticals and associated pharmaceutical inputs into the USA are now subject to a 100% ad valorem duty at US entry. India's exports to the USA are concentrated in low-cost generic medicines and therefore fall largely outside the tariff's targeted scope.
Implications
- — US-based customs brokers and import-entry preparers must update customs declarations immediately to include the 100% ad valorem duty for covered patented-drug consignments — failure to declare the duty exposes importers to underpayment and US customs enforcement actions.
- — Trade-compliance teams at US pharmaceutical distributors and manufacturers must revise tariff classifications and compliance controls before the next shipment arrival — entries using outdated classifications risk retrospective duties or classification disputes.
Unlock the full brief.
Implications — what this forces you to change
Who is affected — which roles and obligations are exposed
What to watch — binding deadlines and enforcement dates
Real-time alerts — delivered the moment a binding change is published
Clarify with AI — turn any brief into a decision for your role
Start free trial
No credit card · $29/month (~₹2,400) after trial · Active in seconds
Source
View on The Hindu